Cardiac performance, status of RAS and oxidative stress in control and MI animals with or without ENP and LOS treatments for 4 weeks starting at 3 weeks after induction of MI
| Parameters | Control | MI | MI + ENP | MI + LOS |
|---|---|---|---|---|
| A. Hemodynamic parameters | ||||
| LVEDP (mmHg) | 4.0 ± 0.2 | 15.9 ± 1.3 | 7.5 ± 0.6 | 6.9 ± 0.5 |
| LVSP (mmHg) | 133 ± 4.9 | 128 ± 3.2 | 131 ± 3.8 | 127 ± 3.9 |
| LV + dP/dt (mmHg/s) | 9,208 ± 1075 | 4,806 ± 745 | 7,690 ± 680 | 7,544 ± 722 |
| LV − dP/dt (mmHg/s) | 8,788 ± 956 | 4,326 ± 590 | 7,248 ± 702 | 7,312 ± 690 |
| B. RAS activity parameters | ||||
| Plasma ANG II (fmol/mL) | 8.3 ± 1.4 | 125 ± 6.9 | 34 ± 3.5 | 192 ± 9.9 |
| Plasma ACE activity (nmol/min per mL) | 51 ± 3.3 | 85 ± 7.1 | 32 ± 2.4 | 145 ± 7.1 |
| LV ACE activity (nmol/min per mg protein) | 0.45 ± 0.03 | 0.69 ± 0.04 | 0.23 ± 0.02 | 0.84 ± 0.05 |
| C. Oxidative stress levels | ||||
| LV MDA (nmol/mg tissue lipids) | 5.9 ± 0.4 | 19.1 ± 0.8 | 12.7 ± 0.3 | 10.1 ± 0.4 |
| LV conjugated dienes formation (nmol/mg tissue lipids) | 33 ± 1.9 | 56 ± 4.9 | 41 ± 3.0 | 37 ± 3.3 |
| LV GSH (μmol/g tissue) | 82 ± 1.6 | 36 ± 4.1 | 74 ± 4.1 | 68 ± 3.7 |
| LV GSSG (μmol/g tissue) | 12.4 ± 0.8 | 25.2 ± 2.6 | 14.2 ± 1.4 | 15.3 ± 1.6 |
Values are mean ± standard error (SE) of 4–6 animals in each group. ENP: enalapril (10 mg/kg per day); LOS: losartan (20 mg/kg per day); MI: myocardial infarction; RAS: renin-angiotensin system; ACE: angiotensin-converting enzyme; LVEDP: LV end diastolic pressure; LVSP: LV systolic pressure; + dP/dt: maximum rate of pressure development; -dP/dt: maximum rate of pressure decay; MDA: malondialdehyde; GSH: reduced glutathione; GSSG: oxidized glutathione. Data are based on the analysis of the information in our papers Shao et al. Am J Physiol Heart Circ Physiol. 2005;288:H2637–46 [116]; and Shao et al. Am J Physiol Heart Circ Physiol. 2005;288:H1674–82 [113]. *P < 0.05 compared with control; †P < 0.05 compared with MI group